Optimizing Treatment for ADHD


“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”

What may be on the horizon for the treatment of attention-deficit/hyperactivity disorder (ADHD)? Matthew Brams, MD, joined Psychiatric Times’ Mental Health Minute to share his insights into a new study of the triple-release formulation of dexmethylphenidate CTx-1301 for adults with ADHD.

There is increased attention on adult ADHD as well as an increased awareness that ADHD has the potential to adversely affect all aspects of patients’ lives. Brams—the principal investigator—explains that this new formulation is associated with an extra 4 hours of efficacy, thus supporting adult patients throughout their active day without the need for multiple dosing or medications.

Dr Brams is currently an assistant professor in the Division of Psychiatry at Baylor College of Medicine. He also serves as director of DePelchin Children’s Center and Bayou City Research, Inc.

Related Videos
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2024 MJH Life Sciences

All rights reserved.